Clinical Study on the Effect of Elevit Pregnancy 2nd & 3rd Trimester (Multi-micronutrients & DHA Supplement) on the Nutritional Status of Pregnant Women During Second and Third Trimester

Healthy Pregnant Women Clinical Trial

Official title:

Effects of Multiple Micronutrients and Docosahexaenoic Acid (DHA) Supplementation During Pregnancy on Maternal Biomarkers and Infant Anthropometric Outcomes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04438928
• Other study ID #: 18366
• Status: Completed
• Phase: N/A
• Start date: September 27, 2016
• Est. completion date: December 5, 2019

Study information

• Verified date: November 2020
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to collect information how adding a soft gel preparation of micronutrients such as vitamins, dietary minerals plus omega-3 fatty acid (docosahexaenoic acid, DHA) to the diet of pregnant women during the 2nd and 3rd trimesters of pregnancy effects the nutritional state of the mother and infants at delivery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 164
• Est. completion date: December 5, 2019
• Est. primary completion date: December 5, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 42 Years

Eligibility

Inclusion Criteria:

• Healthy pregnant Caucasian women aged 18 to 42 years (inclusive) in their 1st - 2nd trimester (gestational age (GA) week 11-14 at screening);

• Hemoglobin (Hg) > 105g/L;

• Inconspicuous fetal anomaly screening;

• Normal ultrasound examination (Ultra Sonography (USG));

• Singleton pregnancy;

• Taking at least 400 mcg folate per day;

• Seronegative for Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis C at screening;

• Pregnant women who, in the opinion of the Investigator, are willing and able to participate in all scheduled visits, to adhere to the supplementation plan, to laboratory tests and to all other study related procedures according to the clinical protocol;

• Pregnant women providing a personally signed and dated given informed consent to participate in the study and to adhere to all study procedures indicating that they have been informed of all pertinent aspects of the trial and that they understood and accepted these, prior to admission to the study.

Exclusion Criteria:

• Physical (including vital signs e.g. blood pressure and pulse rate), hematological and clinical-chemical parameters deviating from normal and with clinical relevance;

• Any infection (acute or chronic) at screening and baseline;

• Any current metabolic diseases (e.g. diabetes, hypothyroidism);

• Less than 12 months from previous delivery;

• Any history or current diseases, which are associated with malabsorption, or other severe diseases of the gastrointestinal tract (e.g. chronic inflammatory bowel disease, iron accumulation, iron utilization disorders); Any history or current neurological, cardiac, endocrine or bleeding disorders;

• Specific diets (e.g. vegan vegetarian, celiac, lactose free);

• Body mass index (BMI) < 18 or >30 kg/m2;

• Pregnant women already taking DHA/multivitamin supplements (except folate or iron);

• Diagnosed or suspected malignant or premalignant disease;

• Current clinically significant depression;

• Current intake of pharmaceuticals or dietary supplements which may interact with any of the ingredients of the trial treatment (i.e. fluoroquinolones, bisphosphonates, levodopa, levothyroxine, penicillamine, antibiotics containing tetracycline or trietine);

• History of or current diseases where vitamin, mineral, trace element or DHA supplementation might be not recommended /contraindicated [such as sickle cell anemia, copper metabolism disorders (Wilson's disease), renal disease, nephrolithiasis, urolithiasis, hypercalcemia, hypercalciuria, hepatobiliary diseases, existing hypervitaminosis, iron metabolism disorders, hypermagnesemia];

• Severe Hyperemesis gravidarum;

• Previous adverse birth outcomes (e.g. small for gestational age, low birth weight, premature birth, stillbirth, more than two consecutive spontaneous abortions);

• Previous adverse pregnancy outcomes (e.g. gestational diabetes);

• Diagnosed congenital abnormalities in current or previous pregnancy;

• Known carrier or affected with a genetic disease or condition (e.g. mutation carrier for autosomal recessive diseases);

• History of or current abuse of drugs, alcohol or other substances;

• Current smokers and women who smoked during current pregnancy;

• Any history of hypersensitivity or known allergy to any of the ingredients of the study supplement.

Related Conditions & MeSH terms

• Healthy Pregnant Women

Intervention

Dietary Supplement:
• Elevit Pregnancy 2nd & 3rd Trimester
Once daily micronutrient plus DHA supplementation (Multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules)

Other:
• Non-Supplement
Control study group of pregnant women non-supplemented with multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules

Locations

Country	Name	City	State
Italy	ASST Fatebenefratelli Sacco	Milano	Lombardia
Italy	ASST Fatebenefratelli Sacco	Milano	Lombardia

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Maternal Food Frequency Questionnaire FFQ	Focus on foods providing DHA	Up to GA week 34-36
Primary	Change from baseline: Blood RBC DHA/wt% TFA	In order to assess the beneficial effects of supplementation with micronutrients and DHA (docosahexaenoic acid) during 2nd and 3rd trimesters of pregnancy, the red blood cell (RBC) DHA weight percent of total fatty acids (DHA wt% TFA) will be measured compared to baseline as primary maternal variable.; Gestational age is a measure of the age of a pregnancy which is taken from the beginning of the woman's last menstrual period (LMP), or the corresponding age of the gestation as estimated by a more accurate method if available. Such methods include adding 14 days to a known duration since fertilization (as is possible in in vitro fertilization), or by obstetric ultrasonography. The popularity of using such a definition of gestational age is that menstrual periods are essentially always noticed, while there is usually a lack of a convenient way to discern when fertilization occurred.	Baseline: Screening at gestational age (GA) week 11 to 13 and at GA week 24 to 26 and week 34 to 36
Secondary	Change from baseline: Blood RBC EPA/wt% TFA	Red blood cell (RBC) EPA (eicosapentaenoic acid) weight percent of total fatty acids (DHA wt% TFA).	Baseline: Screening at gestational age (GA) week 11 to 13 and at GA week 24 to 26 and week 34 to 36
Secondary	Change from baseline: Blood RBC DHA/TFA ratio %		Baseline: Screening at gestational age (GA) week 11 to 13 and at GA week 24 to 26 and week 34 to 36
Secondary	Change from baseline: Blood RBC Omega 3 index in RBC	The "omega-3 index" reflects the content of EPA plus DHA in erythrocyte membranes expressed as a percentage of total erythrocyte fatty acids.	Baseline: Screening at gestational age (GA) week 11 to 13 and at GA week 24 to 26 and week 34 to 36
Secondary	Change from baseline: Blood 25-hydroxyvitamin D concentration %		Baseline: Screening at gestational age (GA) week 11 to 13 and at GA week 24 to 26 and week 34 to 36
Secondary	Change from baseline: Blood Glutathione (GSH)/oxidized Glutathione (GSSG) ratio %	Glutathione exists in reduced (GSH) and oxidized (GSSG) states. Reduced glutathione is the most abundant antioxidant in aerobic cells and participates in the detoxification of lipid hydroperoxides and hydrogen peroxide exerted by glutathione peroxidases. When cells are exposes to increased oxidative stress levels, GSSG accumulates and the GSH/GSSG ratio decreases.	Baseline: Screening at gestational age (GA) week 11 to 13 and at GA week 24 to 26 and week 34 to 36
Secondary	Change from baseline: Blood Reactive oxygen metabolites (ROMs) concentrations %		Baseline: Screening at gestational age (GA) week 11 to 13 and at GA week 24 to 26 and week 34 to 36
Secondary	Change from baseline: Blood 8-Isoprostane concentration %		Baseline: Screening at gestational age (GA) week 11 to 13 and at GA week 24 to 26 and week 34 to 36
Secondary	Infant sex		At delivery
Secondary	Infant gestational age		At delivery
Secondary	Infant head circumference		At delivery
Secondary	Infant weight measurements		At delivery
Secondary	Infant length measurements		At delivery
Secondary	Infant ponderal index		At delivery
Secondary	Infant skinfold thickness	Triplicate measurements: triceps, biceps, suprailiac, and subscapular on left side with standard skinfold caliper operated with constant pressure of 10 g/mm2)	At delivery
Secondary	Infant Apgar score		At delivery
Secondary	Infant bone density		Up to 10 days after delivery
Secondary	Umbilical cord blood gas analysis	Cord blood sample evaluations in a subset of women undergoing Caesarean section.	At delivery
Secondary	Umbilical cord blood pH analysis	Cord blood sample evaluations in a subset of women undergoing Caesarean section.	At delivery
Secondary	Cord blood metabolomic analysis	Cord blood sample evaluations in a subset of women undergoing Caesarean section.	At delivery
Secondary	Placental weight	Placenta tissue sample evaluation in a subset of women undergoing caesarean section.; Placental efficiency will be estimated through the feto/placental weight (F/P) ratio, calculated as birth weight divided by the placental weight.	At delivery
Secondary	Placental biometric parameters	Placenta tissue sample evaluation in a subset of women undergoing caesarean section.; i.e. larger (D) and smaller (d) diameters of the chorionic elliptical disc, feto/placental weight (F/P ratio)	At delivery
Secondary	Blood, cord blood and placental RBC DHA/wt% TFA	Sample evaluations in a subset of women undergoing Caesarean section.	At delivery
Secondary	Blood, cord blood and placental RBC EPA wt% TFA	Sample evaluations in a subset of women undergoing Caesarean section.	At delivery
Secondary	Blood, cord blood and placental DHA/TFA ratio %	Sample evaluations in a subset of women undergoing Caesarean section.	At delivery
Secondary	Blood, cord blood and placental RBC Omega 3 index	Sample evaluations in a subset of women undergoing Caesarean section.	At delivery
Secondary	Mitochondrial DNA content evaluation in placental tissue and isolated trophoblast cells	mtDNA is a well-accepted molecular marker to assess mitochondria content.; Sample evaluations in a subset of women undergoing Caesarean section.	At delivery
Secondary	IL-6 (Interleukin 6), IL-10 (Interleukin 10) and TNF-a (Tumor Necrosis Factor Alpha) in placental tissue and isolated trophoblast cells	These genes are constitutively expressed in human placenta and are a reliable marker of inflammation.; Sample evaluations in a subset of women undergoing Caesarean section.	At delivery
Secondary	Placental tissue metabolomic analysis	Sample evaluations in a subset of women undergoing Caesarean section.; The rationale for conducting metabolomic analysis is to understand if multi-micronutrient supplement (MMS) supplementation during the second and third trimester of pregnancy influences maternal and infant gestational outcomes (e.g. oxidative stress, placental function).	At delivery
Secondary	Blood, cord blood and placental 8-isoprostane	Sample evaluations in a subset of women undergoing Caesarean section.	At delivery
Secondary	Blood, cord blood and placental reactive oxygen metabolites (ROMs) concentrations %	Sample evaluations in a subset of women undergoing Caesarean section.	At delivery
Secondary	Number of Adverse Events (AEs)		Within 7 days after Delivery
Secondary	Severity of AEs		Within 7 days after Delivery
Secondary	AE relationship to the investigational product		Within 7 days after Delivery